
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
First Wave BioPharma Completes Business Combination with ImmunogenX, Adding Latiglutenase
Details : Through acquisition, First Wave advances its lead product IMGX003 (latiglutenase) for treating celiac disease, currently under Phase II clinical trials.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger
Details : Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : First Wave BioPharma
Deal Size : Undisclosed
Deal Type : Merger

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology
Details : The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patie...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
ImmunogenX and Mayo Clinic Successfully Complete the CeliacShield Trial
Details : CeliacShield Trial is a double-blind, placebo controlled, gluten challenge trial of the efficacy, safety and tolerability of 6-weeks treatment of Latiglutenase (IMGX003) administration in patients with well-controlled celiac disease.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease
Details : The trial will test the safety and efficacy of the company’s lead therapeutic candidate, Latiglutenase (IMGX003).
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Latiglutenase
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
